BNP Paribas Financial Markets Makes New Investment in Stevanato Group S.p.A. (NYSE:STVN)

BNP Paribas Financial Markets purchased a new stake in Stevanato Group S.p.A. (NYSE:STVN - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 48,754 shares of the company's stock, valued at approximately $1,062,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Ameriprise Financial Inc. increased its stake in Stevanato Group by 15.1% in the 4th quarter. Ameriprise Financial Inc. now owns 531,354 shares of the company's stock valued at $11,578,000 after buying an additional 69,550 shares during the last quarter. ArrowMark Colorado Holdings LLC acquired a new stake in Stevanato Group in the 4th quarter valued at $5,312,000. Johnson Financial Group Inc. acquired a new position in shares of Stevanato Group during the 4th quarter worth about $41,000. Hancock Whitney Corp bought a new stake in shares of Stevanato Group in the 4th quarter valued at about $239,000. Finally, Tower Research Capital LLC TRC raised its holdings in shares of Stevanato Group by 202.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 7,413 shares of the company's stock valued at $162,000 after purchasing an additional 4,965 shares during the period.

Wall Street Analysts Forecast Growth

STVN has been the topic of a number of research analyst reports. UBS Group dropped their target price on shares of Stevanato Group from $24.00 to $23.50 and set a "neutral" rating on the stock in a report on Friday, March 7th. William Blair reaffirmed an "outperform" rating on shares of Stevanato Group in a report on Friday, March 7th. Finally, Stephens raised shares of Stevanato Group to a "strong-buy" rating in a report on Monday, April 21st. Two investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of €25.70 ($29.20).

Stevanato Group Stock Performance

STVN traded down €0.37 ($0.42) on Friday, reaching €22.24 ($25.27). The company had a trading volume of 159,565 shares, compared to its average volume of 343,538. Stevanato Group S.p.A. has a fifty-two week low of €16.56 ($18.82) and a fifty-two week high of €25.75 ($29.26). The stock has a market cap of $6.74 billion, a P/E ratio of 47.32, a P/E/G ratio of 7.18 and a beta of 0.51. The company's fifty day moving average is €21.71 and its 200 day moving average is €21.31. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.21 and a current ratio of 1.81.

Stevanato Group (NYSE:STVN - Get Free Report) last announced its quarterly earnings results on Thursday, March 6th. The company reported €0.20 ($0.23) EPS for the quarter, meeting analysts' consensus estimates of €0.20 ($0.23). Stevanato Group had a net margin of 10.47% and a return on equity of 9.86%. The business had revenue of €352.68 million for the quarter, compared to analyst estimates of €346.26 million. As a group, analysts predict that Stevanato Group S.p.A. will post 0.5 earnings per share for the current fiscal year.

Stevanato Group Increases Dividend

The business also recently declared an annual dividend, which will be paid on Thursday, July 17th. Investors of record on Thursday, June 5th will be paid a $0.0613 dividend. The ex-dividend date is Thursday, June 5th. This represents a yield of 0.3%. This is a positive change from Stevanato Group's previous annual dividend of $0.05. Stevanato Group's dividend payout ratio is 11.76%.

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.